Tag: PD-1/PD-L1 Pathway

By Posted on Posted in New Drug Approval, Targeted Therapy, Thasso Post, Theragenomic Medicine Tagged with , , , , , ,

May 18, 2016 –  Over the last two years, biologics  targeting the PD-1/PD-L1 pathway (proteins found on the body’s immune cells and some cancer cells), notably Nivolumab (Opdivo) and Pembrolizumab (Keytruda), have come to the clinic for the treatment of a selection of …

Hope for patients with urothelial carcinoma: Atezolizumab (Tecentriq) approved Read more »

By Posted on Posted in New Indication Approval, Thasso Post, Theragenomic Medicine Tagged with , , , , , , , , , , ,
Immune Checkpoint Regulation: The role of the PD-1/PDL1 pathway.

October 11, 2015 – In recent months, Nivolumab (Opdivo), a human IgG4 anti-PD-1 monoclonal antibody which targets the PD-1 receptor, had been approved first for the treatment of unresectable  or advanced (metastatic) melanoma and secondly for the treatment of advanced (metastatic) squamous non-small cell …

Nivolumab (Opdivo) demonstrates survival benefit in squamous and non-squamous non-small cell lung cancer (NSCLC) Read more »